REPLACE: (Riociguat rEplacing PDE5i therapy evaluated Against Continued PDE5i therapy): A Look at Phase IV Study Data | American Thoracic Society

REPLACE: (Riociguat rEplacing PDE5i therapy evaluated Against Continued PDE5i therapy): A Look at Phase IV Study Data

Thank you

Thank you for joining our webinar today sponsored by Bayer. Industry Innovations Webinars are archived on the ATS YouTube channel.

Contributors

Roxana Sulica, MD

Pulmonologist, Critical Care physician – NYU Langone Health, NY, NY
Director of NYU Langone Health Pulmonary Hypertension Program

To learn more about the serious risks associated with Adempas, please refer to the Prescribing Information (this comes from our website, www.adempasrems.com).
http://labeling.bayerhealthcare.com/html/products/pi/Adempas_PI.pdf

April 21, 2021

Wed 6:30 PM EDT

Duration 1H 0M

This live web event has ended.